Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-28EMA Authorised: Jaypirca (pirtobrutinib) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Jaypirca (pirtobrutinib) for mantle cell lymphoma under conditional approval.
-
CLINICAL_TRIALS trial_result · 2026-01-28Clinical Trial Update: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment [Phase 2]
This update summarizes a Phase 2 trial of zanubrutinib (BGB-3111) in participants with previously treated B-cell lymphomas intolerant to pri…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical trial registry update for the RUBIN platform extension focusing on hematologic malignancies. It is currently recruiting for conditi…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy [Phase 3]
Phase 3 clinical trial evaluating a digital health intervention for self-management and telemonitoring in CAR-T therapy is currently recruit…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial of the oral BTK inhibitor LOXO-305 (pirtobrutinib) in patients with previously treated chronic lymphocy…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluates PRT2527 as a standalone therapy and in combination with zanubrutinib or venetoclax for relapsed/refractor…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating Relmacabtagene autoleucel in combination with sintilimab for relapsed/refractory B-cell lymphomas; …
-
CLINICAL_TRIALS other · 2026-01-21Clinical Trial Update: Avo In R/R And Previously Untreated MCL [Phase 1, Phase 2]
The trial is currently recruiting for an agent named Avo in mantle cell lymphoma, including relapsed/refractory disease and previously untre…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [Phase 1]
Phase 1 study evaluating T cells engineered to co-express kappa and CD28 CARs for relapsed/refractory kappa+ non-Hodgkin lymphoma and chroni…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 study of Rocbrutinib in relapsed or refractory mantle cell lymphoma is active and not recruiting. Sponsor: Guangzhou Lupeng Pharma…
-
CLINICAL_TRIALS trial_result · 2026-01-14Clinical Trial Update: Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance [Phase 2]
This Phase 2 trial evaluated upfront and maintenance obinutuzumab in mantle cell lymphoma treated with the DHAP regimen and MRD-driven maint…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]
This is a Phase 1 trial evaluating anti-CD19 CAR-T cell therapy for relapsed or refractory non-Hodgkin lymphoma. The study is currently recr…
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating ultra-low-dose orbital radiation therapy for Stage I-IV indolent B-cell non-Hodgkin lymphoma and mantle cell lympho…
-
FDA approval · 2026-01-06FDA Approved: BORTEZOMIB — Original Application (Gland Pharma Limited)
FDA approved the original application for Bortezomib from Gland Pharma Limited as a generic injectable, covering indications established for…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. [Phase 2]
Phase 2 trial evaluating consolidation with loncastuximab tesirine after a short course of immunochemotherapy in BTKi-treated or intolerant …
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial at City of Hope is evaluating a three-drug combination of acalabrutinib, obinutuzumab, and glofitamab for relapsed …
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.
This entry covers the MANTLE-FIRST BIO clinical study, which aims to glean biological insights from first relapsed/refractory mantle cell ly…
-
CLINICAL_TRIALS trial_result · 2025-12-30Clinical Trial Update: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]
The Phase 1/Phase 2 trial of TQB3909 tablets for relapsed or refractory mantle cell lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients [Phase 1]
Phase 1 study assessing safety and tolerability of CD19x22 CAR T cells in adolescents and adults with relapsed/refractory B-cell non-Hodgkin…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: The Role of 18F-FDG-PET for Staging and Prognostication
A completed clinical trial update evaluating the role of 18F-FDG-PET imaging for staging and prognostication in mantle cell lymphoma.
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. [Phase 1]
This is a Phase 1 dose-escalation and expansion study evaluating intratumoral ONM-501 alone and in combination with cemiplimab in patients w…
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating ultra low dose radiation delivered before or after a chemotherapy-free targeted therapy in patients w…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 study update for brexucabtagene autoleucel (KTE-X19) in adult Japanese patients with relapsed/refractory mantle cell lymphoma or rel…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of pirtobrutinib in combination with rituximab for Mantle Cell Lymphoma; currently…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma [Phase 1]
An ongoing Phase 1 clinical trial update for AS-1763 in adults with previously treated B-cell malignancies, including chronic lymphocytic le…